2378P Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment

• DOI: 10.1016/j.annonc.2023.09.1027
• Publication Date: 2023-10-20T11:58:04Z
• Authors: V.S. Koshkin; P. Danchaivijitr; W.K. Bae; A. Semenov; Ö. Özyilkan; Y-L. Su; J.A. Arranz Arija; M. Tsujihata; M. Boegemann; M.P. Hendriks; S.P. Neciosup Del...; S. Cheng; E. Rosenbaum; K. Lopez; A. Bavle; C-C. Liu; K. Imai; A. Furka